Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Modular Medical, Inc. is a pre-revenue medical device company developing modular insulin delivery systems for diabetes management. The company is in clinical development stage with no commercial products, burning cash to fund R&D and regulatory approval processes. Stock performance reflects binary clinical/regulatory risk typical of early-stage medical device developers.
Company is developing a modular insulin delivery platform targeting Type 1 and insulin-dependent Type 2 diabetes patients. Business model will eventually center on upfront device sales with recurring consumable revenue (infusion sets, cartridges). Pricing power depends on securing insurance reimbursement codes and demonstrating clinical superiority or cost-effectiveness versus established competitors (Medtronic, Tandem, Insulet). Currently funded through equity raises and potential non-dilutive grants, with no revenue generation.
Clinical trial data releases and milestone achievements (safety, efficacy endpoints)
FDA regulatory submissions and approval decisions (510(k) or PMA pathway progress)
Capital raises and cash runway announcements (dilution concerns with negative FCF)
Partnership or licensing deals with larger medical device companies
Competitive developments in continuous glucose monitoring (CGM) and automated insulin delivery (AID) systems
FDA regulatory approval risk - failure to demonstrate safety/efficacy or receive clearance would render company value near zero
Reimbursement uncertainty - even with FDA approval, inability to secure favorable Medicare/commercial insurance coverage would limit market access
Rapid technological obsolescence in diabetes care - automated insulin delivery and closed-loop systems evolving quickly, risk of being leapfrogged by competitors
Entrenched competitors with established distribution (Medtronic 670G/780G, Tandem Control-IQ, Insulet Omnipod 5) and strong physician relationships
Well-capitalized rivals with integrated CGM+pump ecosystems (Dexcom partnerships) creating switching costs
Potential for large-cap medtech acquirers (Abbott, J&J) to enter or expand in automated insulin delivery space
Severe cash burn with negative $0.0B operating cash flow and -61.6% FCF yield - imminent dilution risk if unable to raise capital
Current ratio of 1.59 provides limited cushion; likely needs equity raise within 12 months based on burn rate
Negative ROE of -245.8% and ROA of -261.0% reflect pre-revenue status with accumulated losses eroding equity base
Market cap near zero suggests significant going concern risk if clinical or regulatory setbacks occur
low - Pre-revenue biotech/medtech companies are largely insulated from GDP cycles. Stock driven by binary clinical/regulatory events rather than economic conditions. Post-commercialization, diabetes device demand is relatively recession-resistant as insulin delivery is medically necessary.
Rising rates negatively impact valuation through higher discount rates applied to distant future cash flows. Pre-revenue companies with long development timelines are particularly sensitive to rate changes as their value is entirely in terminal value. Higher rates also increase cost of capital for future equity raises, potentially forcing more dilutive financings. Fed funds rate and 10-year Treasury yield movements directly affect investor appetite for speculative growth/development-stage equities.
Minimal direct credit exposure given pre-revenue status and lack of commercial operations. Company relies on equity markets rather than debt financing (Debt/Equity of 0.09 indicates minimal leverage). However, tighter credit conditions reduce risk appetite for speculative healthcare equities and can impair ability to raise growth capital.
growth - Highly speculative, binary-outcome investors willing to accept total loss risk for potential multi-bagger returns if FDA approval achieved. Typical holders include biotech-focused venture funds, retail speculators, and development-stage healthcare specialists. Not suitable for value or income investors given negative earnings, no dividends, and balance sheet consumption.
high - Stock exhibits extreme volatility typical of pre-revenue medical device developers. Clinical data releases, FDA interactions, and financing events create sharp price swings. 57.9% one-year decline and 33.3% six-month decline reflect high beta to healthcare innovation sentiment and risk-off moves in speculative growth equities. Expect continued high volatility until commercial revenue visibility emerges.